moxifloxacin has been researched along with np 031112 in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (np 031112) | Trials (np 031112) | Recent Studies (post-2010) (np 031112) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 72 | 5 | 68 |
| Protein | Taxonomy | moxifloxacin (IC50) | np 031112 (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 1.55 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 1.55 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 1.55 | |
| Procathepsin L | Homo sapiens (human) | 1.55 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 1.55 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 1.55 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 1.55 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 1.0865 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.597 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 1.55 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 1.55 | |
| Class A sortase SrtA | Staphylococcus aureus | 3.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and np 031112
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |